Innovative Diagnostic Solutions HiberGene Diagnostics specializes in rapid, highly accurate molecular tests for infectious diseases, including emerging COVID-19 variants and other urgent health threats, making it a prime partner for healthcare providers seeking quick, reliable diagnostic tools.

Regulatory Milestones The company has achieved CE Marking for its COVID-19 and Flu combined test, positioning it well for expansion in European markets and compliance with international medical device regulations, thus opening avenues for global sales.

Expanding Product Portfolio With product lines for meningococcus, GBS, and C. difficile, HiberGene offers a comprehensive suite of infectious disease tests, enabling penetration into diverse clinical and laboratory environments and supporting cross-selling opportunities.

Growing Recognition European Union funding and recent high-profile product launches demonstrate strong validation and market interest, enhancing credibility and facilitating introductions to health authorities, hospitals, and labs worldwide.

Focused Market Niche Targeting near-patient and laboratory settings with cost-effective, easy-to-use tests, HiberGene presents a compelling solution for hospitals and clinics aiming to reduce diagnostic turnaround times and improve patient outcomes.